Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by walkingredon Feb 24, 2017 11:54am
342 Views
Post# 25889517

RE:RE:RE:RE:RE:Feb 24, 2017 Pulmonary Fibrosis News IPF - ProMetic

RE:RE:RE:RE:RE:Feb 24, 2017 Pulmonary Fibrosis News IPF - ProMetic The whole thing was done to mitagate costs, and lessen the risk... while still trying to achieve the "buckshot" effect. Part of the slot machine analogy.  To prove 4050 works in any case. Alone. In combination. before they invest into a large trial with something that could destroy them. I've asked Fred about this before and have posted about it. 

To get people to take 4050 alone, people would have to stop taking something approved already to slow it down.  It's not likely.. doesn't matter what you say about how it works.  If 4050 can be approved in combination and become part of prescribed first line, that's pretty big still.  Go from there.

The trial was a success for the company and that's it, SP not so much. The company has confidence to redo the trial, add a placebo... and let us know about it in another amount of  time (days months years)... with larger trials.

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse